Kamini Velhal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kamini Velhal has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Arpita Roy
Sharda University
1 shared publication - Byong-Hun Jeon
Department of Earth Resources and Environmental Engineering Hanyang University Seoul Republic of Korea
1 shared publication - Jaya Lakkakula
Amity Institute of Biotechnology, Amity University Maharashtra, Mumbai, India
1 shared publication - Krishna Kumar Yadav
Department of VLSI Microelectronics, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai 602105, Tamil Nadu, India
1 shared publication - Mohammed Saeed Alqahtani
Radiological Sciences Department, College of Applied Medical Sciences, King Khalid University, Abha 61421, Saudi Arabia
1 shared publication - Ramesh S. Yamgar
Department of Chemistry, CS’s S.S. and L.S. Patkar College of Arts and Science, V. P. Varde College of Commerce and Economics, Goregaon, Mumbai, India
1 shared publication
Latest Publications
- Open Access
A Promising Review on Cyclodextrin Conjugated Paclitaxel Nanoparticles for Cancer Treatment
This review presented the unique characteristics of different types of cyclodextrin polymers by non-covalent host–guest interactions to synthesize an inclusion complex. Various cancers are treated with different types of modified cyclodextrins, along with the anticancer drug paclitaxel. PTX acts as a mitotic inhibitor, but due to its low dissolution and permeability in aqueous solutions, it causes considerable challenges for drug delivery system (DDS) designs. To enhance the solubility, it is reformulated with derivatives of cyclodextrins using freeze-drying and co-solvent lyophilization methods. The present supramolecular assemblies involve cyclodextrin as a key mediator, which is encapsulated with paclitaxel and their controlled release at the targeted area is highlighted using different DDS. In addition, the application of cyclodextrins in cancer treatment, which reduces the off-target effects, is briefly demonstrated using various types of cancer cell lines. A new nano-formulation of PTX is used to improve the antitumor activity compared to normal PTX DDS in lungs and breast cancer is well defined in the present review.
Open AccessA Promising Review on Cyclodextrin Conjugated Paclitaxel Nanoparticles for Cancer Treatment
This review presented the unique characteristics of different types of cyclodextrin polymers by non-covalent host–guest interactions to synthesize an inclusion complex. Various cancers are treated with different types of modified cyclodextrins, along with the anticancer drug paclitaxel. PTX acts as a mitotic inhibitor, but due to its low dissolution and permeability in aqueous solutions, it causes considerable challenges for drug delivery system (DDS) designs. To enhance the solubility, it is reformulated with derivatives of cyclodextrins using freeze-drying and co-solvent lyophilization methods. The present supramolecular assemblies involve cyclodextrin as a key mediator, which is encapsulated with paclitaxel and their controlled release at the targeted area is highlighted using different DDS. In addition, the application of cyclodextrins in cancer treatment, which reduces the off-target effects, is briefly demonstrated using various types of cancer cell lines. A new nano-formulation of PTX is used to improve the antitumor activity compared to normal PTX DDS in lungs and breast cancer is well defined in the present review.